Key clinical point: Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who respond to salvage chemotherapy immediately before chimeric antigen receptor (CAR) T-cell therapy administration have better survival outcomes than those with stable or progressive disease, irrespective of the administration timing.
Major finding: Patients who did vs did not respond to salvage chemotherapy immediately before receiving CAR T-cell therapy had significantly longer overall survival rates (P < .001). The number of prior lines of salvage chemotherapy or before CAR T-cell infusion was not significantly associated with overall survival (P = .28).
Study details: This single-center, retrospective study included 76 autologous stem cell transplantation-eligible patients with relapsed or refractory DLBCL who received second-line salvage chemotherapy with curative intent, of whom 30 patients achieved partial or complete response and 34 patients (with or without response) eventually received CAR T-cell therapy.
Disclosures: This study did not disclose the funding source. N Doki declared receiving lecture fees from various sources.
Source: Yagi Y et al. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study. Cancer Med. 2023 (Aug 28). doi: 10.1002/cam4.6412